Literature DB >> 22481481

Long-term follow-up of inflammatory cystoid macular edema.

Paris G Tranos1, Konstantinos T Tsaousis, Athanasios N Vakalis, Solon Asteriades, Carlos E Pavesio.   

Abstract

PURPOSE: To determine the long-term functional and anatomical outcome of idiopathic uveitic cystoid macular edema (UCME).
METHODS: A longitudinal retrospective study was undertaken of the medical records of patients with UCME. All individuals were examined in the uveitis Service at the Moorfields Eye Hospital. The main outcome measures were change in visual acuity and anatomical outcome of UCME at diverse time points.
RESULTS: A total of 109 eyes (92 patients) with UCME were included in the analysis. Mean follow-up was 60 ± 45 months (median, 48 months). Mean logarithm of the minimum angle of resolution visual acuity 1 month after the intervention improved significantly (P < 0.001) by 0.21 ± 0.27 and maintained at similar levels throughout the follow-up period. Visual acuity at the final follow-up improved in 75 eyes (69%), was deteriorated in 21 eyes (19%), and remained unchanged in 13 eyes (12%). Younger age and better visual acuity at baseline were associated with more favorable visual outcome (P < 0.001). Optical coherence tomography documentation of improvement or total resolution of UCME was observed in 84 eyes (77%) at the final follow-up.
CONCLUSION: Cystoid macular edema is a major complication in uveitis. Current management provides satisfactory long-term results for the majority of those individuals. Visual acuity 1 month after the intervention is usually indicative of the final functional outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22481481     DOI: 10.1097/IAE.0b013e3182483348

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  5 in total

1.  [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis: Date: 02/07/2014].

Authors:  A Heiligenhaus; B Bertram; C Heinz; L Krause; U Pleyer; J Roider; S Sauer; S Thurau
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

2.  Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema.

Authors:  Marc H Levin; Maxwell Pistilli; Ebenezer Daniel; Sapna S Gangaputra; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; John H Kempen
Journal:  Ophthalmology       Date:  2013-12-12       Impact factor: 12.079

3.  Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema.

Authors:  Alaa E Radwan; Cheryl A Arcinue; Paul Yang; Pichaporn Artornsombudh; Esam M Abu Al-Fadl; C Stephen Foster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-22       Impact factor: 3.117

4.  Predictors for functional and anatomic outcomes in macular edema secondary to non-infectious uveitis.

Authors:  Jessica Matas; Victor Llorenç; Alex Fonollosa; Cristina Esquinas; David Diaz-Valle; Barbara Berasategui; Marina Mesquida; Joseba Artaraz; Jose Rios; Alfredo Adan
Journal:  PLoS One       Date:  2019-01-24       Impact factor: 3.240

Review 5.  Update in treatment of uveitic macular edema.

Authors:  Spyridon Koronis; Panagiotis Stavrakas; Miltiadis Balidis; Nikolaos Kozeis; Paris G Tranos
Journal:  Drug Des Devel Ther       Date:  2019-02-19       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.